Blood test may predict immunotherapy success in cancer patients
NCT ID NCT06116032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find out if certain blood markers can predict how well cancer patients respond to immunotherapy. Researchers will collect blood samples from 1500 people with different types of cancer before and during treatment. Participants will be followed for up to 6 months to see if their cancer shrinks, stays the same, or grows. The goal is to better understand who benefits from these treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can specially trained immune cells flush out hidden HIV?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare